TY - JOUR
T1 - Synchronous peritoneal metastases from lung cancer
T2 - incidence, associated factors, treatment and survival: a Dutch population-based study
AU - Lurvink, Robin J.
AU - Rijken, Anouk
AU - Bakkers, Checca
AU - Aarts, Mieke J.
AU - Kunst, Peter W. A.
AU - van de Borne, Ben E.
AU - van Erning, Felice N.
AU - de Hingh, Ignace H. J. T.
N1 - Funding Information:
The authors thank the registration team of the Netherlands Comprehensive Cancer Registration (IKNL) for the collection of data for the Netherlands Cancer Registry.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/6
Y1 - 2021/6
N2 - Peritoneal metastases (PM) from lung cancer are rare and it is unknown how they affect the prognosis of patients with lung cancer. This population-based study aimed to assess the incidence, associated factors, treatment and prognosis of PM from lung cancer. Data from the Netherlands Cancer Registry were used. All patients diagnosed with lung cancer between 2008 and 2018 were included. Logistic regression analysis was performed to identify factors associated with the presence of PM. Cox regression analysis was performed to identify factors associated with the overall survival (OS) of patients with PM. Between 2008 and 2018, 129,651 patients were diagnosed with lung cancer, of whom 2533 (2.0%) patients were diagnosed with PM. The European Standardized Rate of PM increased significantly from 0.6 in 2008 to 1.4 in 2018 (p < 0.001). Age between 50 and 74 years, T3-4 tumour stage, N2-3 nodal stage, tumour morphology of a small cell lung cancer or adenocarcinoma, and the presence of systemic metastases were associated with the presence of PM. The median OS of patients with PM was 2.5 months. Older age, male sex, T3-4 tumour stage, N2-3 nodal stage, not receiving systemic treatment, and the presence of systemic metastases were associated with a worse OS. Synchronous PM were diagnosed in 2.0% of patients with lung cancer and resulted in a very poor survival.
AB - Peritoneal metastases (PM) from lung cancer are rare and it is unknown how they affect the prognosis of patients with lung cancer. This population-based study aimed to assess the incidence, associated factors, treatment and prognosis of PM from lung cancer. Data from the Netherlands Cancer Registry were used. All patients diagnosed with lung cancer between 2008 and 2018 were included. Logistic regression analysis was performed to identify factors associated with the presence of PM. Cox regression analysis was performed to identify factors associated with the overall survival (OS) of patients with PM. Between 2008 and 2018, 129,651 patients were diagnosed with lung cancer, of whom 2533 (2.0%) patients were diagnosed with PM. The European Standardized Rate of PM increased significantly from 0.6 in 2008 to 1.4 in 2018 (p < 0.001). Age between 50 and 74 years, T3-4 tumour stage, N2-3 nodal stage, tumour morphology of a small cell lung cancer or adenocarcinoma, and the presence of systemic metastases were associated with the presence of PM. The median OS of patients with PM was 2.5 months. Older age, male sex, T3-4 tumour stage, N2-3 nodal stage, not receiving systemic treatment, and the presence of systemic metastases were associated with a worse OS. Synchronous PM were diagnosed in 2.0% of patients with lung cancer and resulted in a very poor survival.
KW - Epidemiology
KW - Lung neoplasms
KW - Neoplasm metastasis
KW - Peritoneal neoplasms
KW - Real world data
KW - PERFORMANCE STATUS
KW - PROGNOSIS
KW - STAGE
KW - CARCINOMATOSIS
U2 - 10.1007/s10585-021-10085-z
DO - 10.1007/s10585-021-10085-z
M3 - Article
C2 - 33738641
SN - 0262-0898
VL - 38
SP - 295
EP - 303
JO - Clinical & Experimental Metastasis
JF - Clinical & Experimental Metastasis
IS - 3
ER -